BL20-MMAE
BL20-MMAE is an antibody-drug conjugate targeting ROR1, which is formed by conjugating an anti-ROR1 antibody with the Auristatin payload MMAE (HY-15162) via a BL20 linker.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 2765612-38-0
- Formule: C98H133F2N13O23S2
- Masse moléculaire:1963.30
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform Drug-Linker Conjugates for ADC
More
Activité biologique
BL20-MMAE (10 mg/mL; maintained at 28°C, analyzed after conjugation) conjugates with ROR1-4 antibody to form a purified ADC with a precise drug-to-antibody ratio of 4.0[1].
BL20-MMAE (10 mg/mL; maintained at 28°C, analyzed after conjugation) conjugates with ROR1-12 antibody to form a purified ADC with a precise drug-to-antibody ratio of 4.0[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
BL20-MMAE (administered as ROR1-12-BL20E) (5 mg/kg; i.v.; once weekly; 3 doses) achieves 49% tumor growth inhibition in MDA-MB-231 breast cancer xenografts[1].
BL20-MMAE (administered as ROR1-4-BL20E) (5 mg/kg; i.v.; once weekly; 3 doses) achieves 39% tumor growth inhibition in MDA-MB-231 breast cancer xenografts[1].
BL20-MMAE (administered as ROR1-12-BL20E) (5 mg/kg; i.v.) achieves 51% tumor growth inhibition in H1975 non-small cell lung cancer xenografts[1].
BL20-MMAE (administered as ROR1-4-BL20E) (5 mg/kg; i.v.) achieves 69% tumor growth inhibition in H1975 non-small cell lung cancer xenografts[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:tumor-bearing mice (implanted with JeKo-1 cells, tumors grown to ~100 mm3)[1]
-
Dosage:5 mg/kg
-
Administration:i.v.; on day 0 and day 4
-
Result:Achieved a tumor growth inhibition (TGI) rate of 92% in JeKo-1 tumors by day 18, with 1 out of 6 mice showing partial tumor regression.
Resulted in a statistically significant reduction in tumor volume compared to solvent control (P < 0.0001).
-
Animal Model:tumor-bearing mice (implanted with MDA-MB-231 cells)[1]
-
Dosage:5 mg/kg
-
Administration:i.v.; once weekly; 3 doses
-
Result:Achieved a tumor growth inhibition (TGI) rate of 49% in MDA-MB-231 tumors.\nAchieved a tumor growth inhibition (TGI) rate of 39% in MDA-MB-231 tumors.
-
Animal Model:tumor-bearing mice (implanted with H1975 cells, tumors grown to 100-150 mm3)[1]
-
Dosage:5 mg/kg
-
Administration:i.v.
-
Result:Achieved a tumor growth inhibition (TGI) rate of 51% in H1975 tumors.\nAchieved a tumor growth inhibition (TGI) rate of 69% in H1975 tumors.
Chemical Information
-
CAS No. 2765612-38-0
-
Masse moléculaire 1963.30
-
Formule C98H133F2N13O23S2
-
SMILES
O=C(N1CCOCC1)C(C=C2)=CC=C2SC(C(N(C3=CC(F)=C(C(F)=C3)OCCOCCOCCOCC(N[C@@H](C(C)C)C(N[C@@H](CCCNC(N)=O)C(NC4=CC=C(C=C4)COC(N(C)[C@@H](C(C)C)C(N[C@@H](C(C)C)C(N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(N5[C@](CCC5)([H])[C@H](OC)[C@@H](C)C(N[C@H](C)[C@H](C6=CC=CC=C6)O)=O)=O)=O)=O)=O)=O)=O)=O)C7=O)=O)=C7SC8=CC=C(C=C8)C(N9CCOCC9)=O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
BL20-MMAE Related Classifications
HY-177109 Related Classifications
Powered by Bioz